Non-Alcoholic Steatohepatitis Clinical Trials Market Size

Request Methodology

Non-Alcoholic Steatohepatitis Clinical Trials Market Overview (2023 to 2033)

Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis report by Future Market Insights shows that global sales in 2021 were held at US$ 2.5 billion. With 7%, the projected market growth from 2022 to 2032 is expected to be significantly higher than the historical growth. Phase 3 is expected to be the highest revenue generating for the Non-Alcoholic Steatohepatitis Clinical Trials Market, with a CAGR of around 11.2% from 2022 to 2032.

Attribute	Details
Global Non-Alcoholic Steatohepatitis Clinical Trials Market (2022)	US$ 2.6 billion
Global Non-Alcoholic Steatohepatitis Clinical Trials Market (2032)	US$ 5.1 billion
Global Non-Alcoholic Steatohepatitis Clinical Trials Market (2022 to 2032)	7%
North America Non-Alcoholic Steatohepatitis Clinical Trials Market Share (2022)	40%
The USA Non-Alcoholic Steatohepatitis Clinical Trials Market (2022)	US$ 943.3 million
Key Companies Profiled	Pfizer Inc. Novartis AG Icon Plc LabCorp Allergan Plc Cadila Healthcare Ltd. Shire Plc Eli Lilly Novo Nordisk Gilead Sciences Inc. Glaxosmith Kline Arrowhead Pharmaceuticals

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Revenue of Non-Alcoholic Steatohepatitis Clinical Trials Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the Non-Alcoholic Steatohepatitis Clinical Trials Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Non-Alcoholic Steatohepatitis Clinical Trials Market increased at around 6.2% CAGR, wherein, countries such as the USA, the United Kingdom, China, and Japan held a significant share in the global market.

Additionally, rising technical developments and the rising prevalence of chronic diseases, the rise in the number of surgical procedures, and the aging population are the key factors driving the growth. Owing to this, Non-Alcoholic Steatohepatitis Clinical Trials Market is projected to grow at a CAGR of 7% over the coming 10 years.

How Non-Alcoholic Steatohepatitis Clinical Trials Market Fared during the Pandemic?

Due to reduced patient participation in clinical studies and supply chain interruptions, trials were halted as a result of the pandemic. However, some organizations were able to finish the studies using virtual participants and COVID-compliant screening. Novartis, for example, completed a phase two trial of a specific substance in non-alcoholic steatohepatitis after the drug was identified as a groundbreaking therapy in the United States. Semaglutide will be initiated in non-alcoholic steatohepatitis (NASH) patients in phase 3a in 2021. Novo Nordisk and Gilead Sciences presented the findings of a phase two proof-of-concept experiment in NASH. NASH is the second-leading cause of liver transplants in the United States. NASH is also linked to the development of hepatocellular carcinoma, according to recent research.

Due to pathologist bias, classifying patients into discrete fibrosis phases in NASH trials can be difficult. Sagimet Biosciences is using digital histopathology in its Stage IIb non-alcoholic steatohepatitis (NASH) experiment to achieve better consistent biopsy analysis. In the case of NASH, digital pathology entails histological imaging of biopsy samples, which are then evaluated using Ai Technology (AI) to detect fibrosis changes. In the Phase IIb FASCINATE-2 trial (NCT04906421), Sagimet is cooperating with HistoIndex, a Singapore-based diagnostic business, to investigate TVB-2640.

PathAI and Summit Clinical Research, each based in the United States, are collaborating to create AI-powered tools for evaluating liver pathology. There are 1,000 MR Elastography (MRE) machines in use around the world, however, they have yet to reach the areas with the highest number of NASH clinical trial participants. Its limitation is the high expense of improving MR elastography. Finally, whether it be in Europe or the United States, converting a machine to MR elastography costs roughly $100,000. The cost of the technology is a barrier to adoption, as is the fact that, despite the fact that MRE scans are much more expensive than ordinary Mris, medical insurance does not currently pay additional reimbursements.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Region-wise Analysis

What is the market scenario in different regions of the world for the Non-Alcoholic Steatohepatitis Clinical Trials Market?

Over the projected period, the market in Asia Pacific is expected to grow at the fastest rate of 7.6%. The region's expansion is being fueled by the incidence of diabetes, obesity, and the expanding number of deaths caused by these diseases (which is expected to increase 30-fold by 2030). In 2019, NASH cases are expected to account for 20 to 25 percent of all NAFLD cases, with a prevalence of approximately 5.9% (4.8 percent -7.3 percent) inside the general population in Singapore (all ages). The number of prevalent NASH cases is anticipated to increase by 20% in Hong Kong and South Korea, 25% in Taiwan, and 35% in Singapore between 2019 and 2030. The incidence rates of NAFLD in India are similar to global figures.

NASH is present in around 5% of people with NAFLD. There are no standardized NAFLD screening protocols in India. Fatty liver is usually identified primarily on an ultrasound finding and/or elevated liver enzymes as bulk in noncirrhotic NAFLD and NASH patients who remain asymptomatic. Recent technological advances have resulted in the development of newer as well as better image analysis modes for assessing hyperlipidemia and fibrosis, including magnetic resonance-derived proton density fat portion and MR elastography, which are now being used during early-phase NASH trials to assess the liver amount of fat and fibrosis stage. These are available at a few specialized centers; nevertheless, high costs as well as a paucity of reimbursement can limit their use, particularly in clinical studies.

Country-wise Analysis

The USA Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis

NAFLD is one of the most common chronic liver conditions in the USA It is estimated that about 25% of adults in The USA have NAFLD and of them, about 20% have NASH. With these alarming statistics, the Non-Alcoholic Steatohepatitis Clinical Trials market in The USA is expected to reach a valuation of US$ 1.9 billion by 2032, at a CAGR of 7.5% from 2022 to 2032.

The United Kingdom Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis

A Study indicates that one in eight adults in the United Kingdom may have NASH. It indicates that the prevalence of non-alcohol-related steatohepatitis in the United Kingdom adults could be as high as 12%. Owing to these figures, the market for Non-Alcoholic Steatohepatitis Clinical Trials Market in the United Kingdom stood at around US$ 100 million in 2021. With a CAGR of 7.6%, the market is projected to reach a valuation of US$ 222.2 million by 2032.

Japan Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis

The prevalence of NAFLD in the Japanese population rose from 12.6 - 12.9% of the population in the early 1990s to 24.6 - 34.7% of the population in the early 2000s. At present, the prevalence of NASH in Japan is estimated to be 1.9 - 2.7%. In 2021, Non-Alcoholic Steatohepatitis Clinical Trials Market in Japan was held at US$ 116 million, which is expected to swell to US$ 211 million by 2032.

South Korea Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis

The market for Non-Alcoholic Steatohepatitis Clinical Trials in South Korea accounted for US$ 48.3 million. With an absolute dollar opportunity of around US$ 50 million from 2022 to 2032, the market is projected to reach a valuation of US$ 102 million by 2032.

Category-wise Analysis

What are the insights of different phases in the Non-Alcoholic Steatohepatitis Clinical Trials Market?

In 2021, phase III clinical trials accounted for around 40% of global sales. Phase III studies are known for their high expenditures. A single phase III study, for example, costs around US$ 100 million. As a result, the failure of these studies has a significant economic impact just on sponsors. A Phase III trial collects further information on the drug's safety and efficacy by evaluating additional populations and doses, as well as combining it with other medications. Intelligent, quantitative radiography in association with other diagnostic markers for NASH is the most effective and cost-effective technique to identify and follow NASH patients for clinical trials. All Phase 3 NASH studies must include at least two people, according to existing FDA standards.

What is the market scenario of different study designs in the Non-Alcoholic Steatohepatitis Clinical Trials Market?

In 2021, the interventional category led the market with a share of around 45.5%. There were 84 active intervention studies involving patients enrolled in December 2019 to examine the treatment effectiveness of NASH treatments. The bulk of these trials is looking into innovative medications as targeted therapies, with some looking into NASH treatment in combination. The FDA and the EMA recognized that a histopathological study of cell samples taken from a liver biopsy is the most reliable technique to diagnose NASH. Biomarkers are a subject of controversy between the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).

The FDA highly advises using a biomarker signature technique in phase 2 of a trial. The EMA neither prohibits nor requires the implementation of such a method in stage 2, but it does not require it. Intervention trialists are all in high demand as a result. During the projection period, expanded access trials, also called compassionate use tests, are predicted to rise at the fastest CAGR of 7.7%. Patients with serious illness conditions may be able to receive treatment even in a clinical trial if no satisfactory medicines are available. Increased development in NASH clinical trial methodologies is projected to drive the expanded entry trials market.

Competitive Analysis

Some of the key companies operating in the Non-Alcoholic Steatohepatitis Clinical Trials Market include Pfizer Inc., Novartis AG, Icon Plc, LabCorp, Allergan Plc, Cadila Healthcare Ltd., Shire Plc, Eli Lilly, Novo Nordisk, Gilead Sciences Inc., Glaxosmith Kline, and Arrowhead Pharmaceuticals.

Market participants are pursuing a number of strategic activities, including new partnership agreements, collaborations, mergers and acquisitions, geographic expansion, and strengthening their services and production facilities in order to gain a competitive advantage.

Some of the key developments in the Non-Alcoholic Steatohepatitis Clinical Trials Market are:

In March 2021, Gilead Technologies, Inc. and Nordisk Nordisk announced that their non-alcoholic steatohepatitis study alliance had been enlarged. The firms would conduct a Phase 2b double-blind, placebo-controlled research in people with compensated cirrhosis (F4) due to NASH to examine the safety and efficacy of Novo Nordisk's semaglutide, a GLP-1 receptor agonist.
In November 2021, with a US$ 1 Bn asset transaction with Arrowhead Pharmaceuticals, GlaxoSmithKline announced that it is undertaking its first effort to address the fatty liver illness known as non-alcoholic steatohepatitis (NASH). With a US$ 80 million license agreement with Pliant Therapeutics in October 2019, Novartis acquired another non-alcoholic steatohepatitis pharmaceutical candidate to its pipeline.
In January 2021, Terns Pharmaceuticals launched NASH prospects in clinical development. Following leasing three NASH candidates, the business received an investment of US$ 87 million from Eli Lilly and Deerfield Management.

Market Segments Covered in Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis

By Study Design:

Interventional
Observational
Expanded Access

By Phase:

Phase 1
Phase 2
Phase 3
Phase 4

By Region:

North America
Latin America
Asia-Pacific (APAC)
Middle East and Africa (MEA)
Europe

Frequently Asked Questions

How much is the current worth of the Non-Alcoholic Steatohepatitis Clinical Trials Market?

The Non-Alcoholic Steatohepatitis Clinical Trials Market is worth more than US$ 2.6 billion at present.

What are the sales of Non-Alcoholic Steatohepatitis Clinical Trials Market?

The value of the Non-Alcoholic Steatohepatitis Clinical Trials Market is projected to increase at a CAGR of around 7% from 2022 to 2032.

What was the last 5 year’s market CAGR?

The value of the Non-Alcoholic Steatohepatitis Clinical Trials Market increased at a CAGR of around 6.2% from 2017 to 2021.

What is a key trend shaping the growth of the market?

Phase III Non-Alcoholic Steatohepatitis Clinical Trials are expected to get augmented in the forthcoming years.

Which are the top 5 countries driving demand for Non-Alcoholic Steatohepatitis Clinical Trials Market?

The top 5 countries are the USA, the United Kingdom, China, Japan, and South Korea

Table of Content

1. Executive Summary | Non-Alcoholic Steatohepatitis Clinical Trials Market

1.1. Global Market Outlook

1.2. Summary of Statistics

1.3. Key Market Characteristics & Attributes

1.4. Fact.MR Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

3.1. Risk Assessment

3.1.1. COVID-19 Crisis and Impact on the Market

3.1.2. COVID-19 Impact Benchmark with Previous Crisis

3.1.3. Impact on Market Value (US$ million)

3.1.4. Assessment by Key Countries

3.1.5. Assessment by Key Market Segments

3.1.6. Action Points and Recommendation for Suppliers

3.2. Key Trends Impacting the Market

3.3. Formulation and Product Development Trends

4. Market Background and Foundation Data Points

4.1. Global Market (US$ million)

4.2. Market Opportunity Assessment (US$ million)

4.2.1. Total Available Market

4.2.2. Serviceable Addressable Market

4.2.3. Serviceable Obtainable Market

4.3. Market Scenario Forecast

4.3.1. Demand in optimistic Scenario

4.3.2. Demand in Likely Scenario

4.3.3. Demand in Conservative Scenario

4.4. Investment Feasibility Analysis

4.4.1. Investment in Established Markets

4.4.1.1. In Short Term

4.4.1.2. In Long Term

4.4.2. Investment in Emerging Markets

4.4.2.1. In Short Term

4.4.2.2. In Long Term

4.5. Forecast Factors - Relevance & Impact

4.5.1. Top Companies Historical Growth

4.5.2. Global Market Growth

4.5.3. Adoption Rate, By Country

4.6. Market Dynamics

4.6.1. Market Driving Factors and Impact Assessment

4.6.2. Prominent Market Challenges and Impact Assessment

4.6.3. Market Opportunities

4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

5.2. Banking on with Segments High Incremental Opportunity

5.3. Peer Benchmarking

6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032

6.1. Historical Market Analysis, 2017 to 2021

6.2. Current and Future Market Projections, 2022 to 2032

6.3. Y-o-Y Growth Trend Analysis

7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032

7.1. Historical Market Value (US$ million) Analysis, 2017 to 2021

7.2. Current and Future Market Value (US$ million) Projections, 2022 to 2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Study Design

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ million) Analysis By Study Design, 2017 to 2021

8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Study Design, 2022 to 2032

8.3.1. Interventional

8.3.2. Observational

8.3.3. Expanded Access

8.4. Market Attractiveness Analysis By Study Design

9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Phase

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ million) Analysis By Phase, 2017 to 2021

9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Phase, 2022 to 2032

9.3.1. Phase 1

9.3.2. Phase 2

9.3.3. Phase 3

9.3.4. Phase 4

9.4. Market Attractiveness Analysis By Phase

10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region

10.1. Introduction

10.2. Historical Market Size (US$ million) Analysis By Region, 2017 to 2021

10.3. Current Market Size (US$ million) & Analysis and Forecast By Region, 2022 to 2032

10.3.1. North America

10.3.2. Latin America

10.3.3. Europe

10.3.4. Asia Pacific

10.3.5. Middle East and Africa (MEA)

10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032

11.1. Introduction

11.2. Pricing Analysis

11.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

11.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032

11.4.1. By Country

11.4.1.1. The USA

11.4.1.2. Canada

11.4.1.3. Rest of North America

11.4.2. By Study Design

11.4.3. By Phase

11.5. Market Attractiveness Analysis

11.5.1. By Country

11.5.2. By Study Design

11.5.3. By Phase

12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032

12.1. Introduction

12.2. Pricing Analysis

12.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

12.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032

12.4.1. By Country

12.4.1.1. Brazil

12.4.1.2. Mexico

12.4.1.3. Rest of Latin America

12.4.2. By Study Design

12.4.3. By Phase

12.5. Market Attractiveness Analysis

12.5.1. By Country

12.5.2. By Study Design

12.5.3. By Phase

13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032

13.1. Introduction

13.2. Pricing Analysis

13.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

13.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032

13.4.1. By Country

13.4.1.1. Germany

13.4.1.2. France

13.4.1.3. The United Kingdom.

13.4.1.4. Italy

13.4.1.5. Benelux

13.4.1.6. Nordic Countries

13.4.1.7. Rest of Europe

13.4.2. By Study Design

13.4.3. By Phase

13.5. Market Attractiveness Analysis

13.5.1. By Country

13.5.2. By Study Design

13.5.3. By Phase

14. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032

14.1. Introduction

14.2. Pricing Analysis

14.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

14.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032

14.4.1. By Country

14.4.1.1. China

14.4.1.2. Japan

14.4.1.3. South Korea

14.4.1.4. Rest of Asia Pacific

14.4.2. By Study Design

14.4.3. By Phase

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Study Design

14.5.3. By Phase

15. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032

15.1. Introduction

15.2. Pricing Analysis

15.3. Historical Market Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021

15.4. Market Value (US$ million) & Forecast By Market Taxonomy, 2022 to 2032

15.4.1. By Country

15.4.1.1. GCC Countries

15.4.1.2. South Africa

15.4.1.3. Turkey

15.4.1.4. Rest of Middle East and Africa

15.4.2. By Study Design

15.4.3. By Phase

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Study Design

15.5.3. By Phase

16. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032

16.1. Introduction

16.1.1. Market Value Proportion Analysis, By Key Countries

16.1.2. Global Vs. Country Growth Comparison

16.2. US Market Analysis

16.2.1. Value Proportion Analysis by Market Taxonomy

16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.2.2.1. By Study Design

16.2.2.2. By Phase

16.3. Canada Market Analysis

16.3.1. Value Proportion Analysis by Market Taxonomy

16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.3.2.1. By Study Design

16.3.2.2. By Phase

16.4. Mexico Market Analysis

16.4.1. Value Proportion Analysis by Market Taxonomy

16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.4.2.1. By Study Design

16.4.2.2. By Phase

16.5. Brazil Market Analysis

16.5.1. Value Proportion Analysis by Market Taxonomy

16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.5.2.1. By Study Design

16.5.2.2. By Phase

16.6. Germany Market Analysis

16.6.1. Value Proportion Analysis by Market Taxonomy

16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.6.2.1. By Study Design

16.6.2.2. By Phase

16.7. France Market Analysis

16.7.1. Value Proportion Analysis by Market Taxonomy

16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.7.2.1. By Study Design

16.7.2.2. By Phase

16.8. Italy Market Analysis

16.8.1. Value Proportion Analysis by Market Taxonomy

16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.8.2.1. By Study Design

16.8.2.2. By Phase

16.9. BENELUX Market Analysis

16.9.1. Value Proportion Analysis by Market Taxonomy

16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.9.2.1. By Study Design

16.9.2.2. By Phase

16.10. UK Market Analysis

16.10.1. Value Proportion Analysis by Market Taxonomy

16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.10.2.1. By Study Design

16.10.2.2. By Phase

16.11. Nordic Countries Market Analysis

16.11.1. Value Proportion Analysis by Market Taxonomy

16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.11.2.1. By Study Design

16.11.2.2. By Phase

16.12. China Market Analysis

16.12.1. Value Proportion Analysis by Market Taxonomy

16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.12.2.1. By Study Design

16.12.2.2. By Phase

16.13. Japan Market Analysis

16.13.1. Value Proportion Analysis by Market Taxonomy

16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.13.2.1. By Study Design

16.13.2.2. By Phase

16.14. South Korea Market Analysis

16.14.1. Value Proportion Analysis by Market Taxonomy

16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.14.2.1. By Study Design

16.14.2.2. By Phase

16.15. GCC Countries Market Analysis

16.15.1. Value Proportion Analysis by Market Taxonomy

16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.15.2.1. By Study Design

16.15.2.2. By Phase

16.16. South Africa Market Analysis

16.16.1. Value Proportion Analysis by Market Taxonomy

16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.16.2.1. By Study Design

16.16.2.2. By Phase

16.17. Turkey Market Analysis

16.17.1. Value Proportion Analysis by Market Taxonomy

16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017 to 2032

16.17.2.1. By Study Design

16.17.2.2. By Phase

16.17.3. Competition Landscape and Player Concentration in the Country

17. Market Structure Analysis

17.1. Market Analysis by Tier of Companies

17.2. Market Concentration

17.3. Market Share Analysis of Top Players

17.4. Market Presence Analysis

17.4.1. By Regional footprint of Players

17.4.2. Product footprint by Players

18. Competition Analysis

18.1. Competition Dashboard

18.2. Competition Benchmarking

18.3. Competition Deep Dive

18.3.1. Pfizer Inc.

18.3.1.1. Overview

18.3.1.2. Product Portfolio

18.3.1.3. Sales Footprint

18.3.1.4. Strategy Overview

18.3.2. Novartis AG

18.3.3. Icon Plc

18.3.4. LabCorp

18.3.5. Allergan Plc

18.3.6. Cadila Healthcare Ltd.

18.3.7. Shire Plc

18.3.8. Eli Lilly

18.3.9. Novo Nordisk

18.3.10. Gilead Sciences Inc.

18.3.11. Glaxosmith Kline

18.3.12. Arrowhead Pharmaceuticals

19. Assumptions and Acronyms Used

20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Mn), By Study Design, 2017 to 2021

Table 2: Global Market Value (US$ Mn), By Study Design, 2022 to 2032

Table 3: Global Market Value (US$ Mn), By Phase, 2017 to 2021

Table 4: Global Market Value (US$ Mn), By Phase, 2022 to 2032

Table 5: Global Market, By Region, 2017 to 2021

Table 6: Global Market, By Region, 2022 to 2032

Table 7: North America Market Value (US$ Mn), By Study Design, 2017 to 2021

Table 8: North America Market Value (US$ Mn), By Study Design, 2022 to 2032

Table 9: North America Market Value (US$ Mn), By Phase, 2017 to 2021

Table 10: North America Market Value (US$ Mn), By Phase, 2022 to 2032

Table 11: North America Market, By Country, 2017 to 2021

Table 12: North America Market, By Country, 2022 to 2032

Table 13: Latin America Market Value (US$ Mn), By Study Design, 2017 to 2021

Table 14: Latin America Market Value (US$ Mn), By Study Design, 2022 to 2032

Table 15: Latin America Market Value (US$ Mn), By Phase, 2017 to 2021

Table 16: Latin America Market Value (US$ Mn), By Phase, 2022 to 2032

Table 17: Latin America Market, By Country, 2017 to 2021

Table 18: Latin America Market, By Country, 2022 to 2032

Table 19: Europe Market Value (US$ Mn), By Study Design, 2017 to 2021

Table 20: Europe Market Value (US$ Mn), By Study Design, 2022 to 2032

Table 21: Europe Market Value (US$ Mn), By Phase, 2017 to 2021

Table 22: Europe Market Value (US$ Mn), By Phase, 2022 to 2032

Table 23: Europe Market, By Country, 2017 to 2021

Table 24: Europe Market, By Country, 2022 to 2032

Table 25: Asia Pacific Market Value (US$ Mn), By Study Design, 2017 to 2021

Table 26: Asia Pacific Market Value (US$ Mn), By Study Design, 2022 to 2032

Table 27: Asia Pacific Market Value (US$ Mn), By Phase, 2017 to 2021

Table 28: Asia Pacific Market Value (US$ Mn), By Phase, 2022 to 2032

Table 29: Asia Pacific Market, By Country, 2017 to 2021

Table 30: Asia Pacific Market, By Country, 2022 to 2032

Table 31: MEA Market Value (US$ Mn), By Study Design, 2017 to 2021

Table 32: MEA Market Value (US$ Mn), By Study Design, 2022 to 2032

Table 33: MEA Market Value (US$ Mn), By Phase, 2017 to 2021

Table 34: MEA Market Value (US$ Mn), By Phase, 2022 to 2032

Table 35: MEA Market, By Country, 2017 to 2021

Table 36: MEA Market, By Country, 2022 to 2032

Table 37: Global Market Incremental $ Opportunity, By Study Design, 2017 to 2021

Table 38: Global Market Incremental $ Opportunity, By Phase, 2022 to 2032

Table 39: Global Market Incremental $ Opportunity, By Region, 2022 to 2032

Table 40: North America Market Incremental $ Opportunity, By Study Design, 2017 to 2021

Table 41: North America Market Incremental $ Opportunity, By Phase, 2022 to 2032

Table 42: North America Market Incremental $ Opportunity, By Country, 2022 to 2032

Table 43: Latin America Market Incremental $ Opportunity, By Study Design, 2017 to 2021

Table 44: Latin America Market Incremental $ Opportunity, By Phase, 2022 to 2032

Table 45: Latin America Market Incremental $ Opportunity, By Country, 2022 to 2032

Table 46: Europe Market Incremental $ Opportunity, By Study Design, 2017 to 2021

Table 47: Europe Market Incremental $ Opportunity, By Phase, 2022 to 2032

Table 48: Europe Market Incremental $ Opportunity, By Country, 2022 to 2032

Table 49: Asia Pacific Market Incremental $ Opportunity, By Study Design, 2017 to 2021

Table 50: Asia Pacific Market Incremental $ Opportunity, By Phase, 2022 to 2032

Table 51: Asia Pacific Market Incremental $ Opportunity, By Country, 2022 to 2032

Table 52: MEA Market Incremental $ Opportunity, By Study Design, 2017 to 2021

Table 53: MEA Market Incremental $ Opportunity, By Phase, 2022 to 2032

Table 54: MEA Market Incremental $ Opportunity, By Country, 2022 to 2032

List of Charts

Figure 1: Global Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032

Figure 2: Global Market Absolute $ Historical Gain (2017 to 2021) and Opportunity (2022 to 2032), US$ million

Figure 3: Global Market Share, By Study Design, 2022 to 2032

Figure 4: Global Market Y-o-Y Growth Projections, By Study Design - 2022 to 2032

Figure 5: Global Market Attractiveness Index, By Study Design - 2022 to 2032

Figure 6: Global Market Share, By Phase, 2022 to 2032

Figure 7: Global Market Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 8: Global Market Attractiveness Index, By Phase - 2022 to 2032

Figure 9: Global Market Share, By Region, 2022 to 2032

Figure 10: Global Market Y-o-Y Growth Projections, By Region - 2022 to 2032

Figure 11: Global Market Attractiveness Index, By Region - 2022 to 2032

Figure 12: North America Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032

Figure 13: North America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million

Figure 14: North America Market Share, By Study Design, 2022 to 2032

Figure 15: North America Market Y-o-Y Growth Projections, By Study Design - 2022 to 2032

Figure 16: North America Market Attractiveness Index, By Study Design - 2022 to 2032

Figure 17: North America Market Share, By Phase, 2022 to 2032

Figure 18: North America Market Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 19: North America Market Attractiveness Index, By Phase - 2022 to 2032

Figure 20: North America Market Share, By Country, 2022 to 2032

Figure 21: North America Market Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 22: North America Market Attractiveness Index, By Country - 2022 to 2032

Figure 23: Latin America Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032

Figure 24: Latin America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million

Figure 25: Latin America Market Share, By Study Design, 2022 to 2032

Figure 26: Latin America Market Y-o-Y Growth Projections, By Study Design - 2022 to 2032

Figure 27: Latin America Market Attractiveness Index, By Study Design - 2022 to 2032

Figure 28: Latin America Market Share, By Phase, 2022 to 2032

Figure 29: Latin America Market Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 30: Latin America Market Attractiveness Index, By Phase - 2022 to 2032

Figure 31: Latin America Market Share, By Country, 2022 to 2032

Figure 32: Latin America Market Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 33: Latin America Market Attractiveness Index, By Country - 2022 to 2032

Figure 34: Europe Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032

Figure 35: Europe Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million

Figure 36: Europe Market Share, By Study Design, 2022 to 2032

Figure 37: Europe Market Y-o-Y Growth Projections, By Study Design - 2022 to 2032

Figure 38: Europe Market Attractiveness Index, By Study Design - 2022 to 2032

Figure 39: Europe Market Share, By Phase, 2022 to 2032

Figure 40: Europe Market Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 41: Europe Market Attractiveness Index, By Phase - 2022 to 2032

Figure 42: Europe Market Share, By Country, 2022 to 2032

Figure 43: Europe Market Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 44: Europe Market Attractiveness Index, By Country - 2022 to 2032

Figure 45: MEA Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032

Figure 46: MEA Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million

Figure 47: MEA Market Share, By Study Design, 2022 to 2032

Figure 48: MEA Market Y-o-Y Growth Projections, By Study Design - 2022 to 2032

Figure 49: MEA Market Attractiveness Index, By Study Design - 2022 to 2032

Figure 50: MEA Market Share, By Phase, 2022 to 2032

Figure 51: MEA Market Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 52: MEA Market Attractiveness Index, By Phase - 2022 to 2032

Figure 53: MEA Market Share, By Country, 2022 to 2032

Figure 54: MEA Market Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 55: MEA Market Attractiveness Index, By Country - 2022 to 2032

Figure 56: Asia Pacific Market Value (US$ million) and Year-on-Year Growth, 2017 to 2032

Figure 57: Asia Pacific Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ million

Figure 58: Asia Pacific Market Share, By Study Design, 2022 to 2032

Figure 59: Asia Pacific Market Y-o-Y Growth Projections, By Study Design - 2022 to 2032

Figure 60: Asia Pacific Market Attractiveness Index, By Study Design - 2022 to 2032

Figure 61: Asia Pacific Market Share, By Phase, 2022 to 2032

Figure 62: Asia Pacific Market Y-o-Y Growth Projections, By Phase - 2022 to 2032

Figure 63: Asia Pacific Market Attractiveness Index, By Phase - 2022 to 2032

Figure 64: Asia Pacific Market Share, By Country, 2022 to 2032

Figure 65: Asia Pacific Market Y-o-Y Growth Projections, By Country - 2022 to 2032

Figure 66: Asia Pacific Market Attractiveness Index, By Country - 2022 to 2032

Figure 67: US Market Value (US$ million) and Forecast, 2022 to 2032

Figure 68: US Market Share, By Study Design, 2021

Figure 69: US Market Share, By Phase, 2021

Figure 70: Canada Market Value (US$ million) and Forecast, 2022 to 2032

Figure 71: Canada Market Share, By Study Design, 2021

Figure 72: Canada Market Share, By Phase, 2021

Figure 73: Brazil Market Value (US$ million) and Forecast, 2022 to 2032

Figure 74: Brazil Market Share, By Study Design, 2021

Figure 75: Brazil Market Share, By Phase, 2021

Figure 76: Mexico Market Value (US$ million) and Forecast, 2022 to 2032

Figure 77: Mexico Market Share, By Study Design, 2021

Figure 78: Mexico Market Share, By Phase, 2021

Figure 79: Germany Market Value (US$ million) and Forecast, 2022 to 2032

Figure 80: Germany Market Share, By Study Design, 2021

Figure 81: Germany Market Share, By Phase, 2021

Figure 82: The United Kingdom Market Value (US$ million) and Forecast, 2022 to 2032

Figure 83: The United Kingdom Market Share, By Study Design, 2021

Figure 84: The United Kingdom Market Share, By Phase, 2021

Figure 85: France Market Value (US$ million) and Forecast, 2022 to 2032

Figure 86: France Market Share, By Study Design, 2021

Figure 87: France Market Share, By Phase, 2021

Figure 88: Italy Market Value (US$ million) and Forecast, 2022 to 2032

Figure 89: Italy Market Share, By Study Design, 2021

Figure 90: Italy Market Share, By Phase, 2021

Figure 91: BENELUX Market Value (US$ million) and Forecast, 2022 to 2032

Figure 92: BENELUX Market Share, By Study Design, 2021

Figure 93: BENELUX Market Share, By Phase, 2021

Figure 94: Nordic Countries Market Value (US$ million) and Forecast, 2022 to 2032

Figure 95: Nordic Countries Market Share, By Study Design, 2021

Figure 96: Nordic Countries Market Share, By Phase, 2021

Figure 97: China Market Value (US$ million) and Forecast, 2022 to 2032

Figure 98: China Market Share, By Study Design, 2021

Figure 99: China Market Share, By Phase, 2021

Figure 100: Japan Market Value (US$ million) and Forecast, 2022 to 2032

Figure 101: Japan Market Share, By Study Design, 2021

Figure 102: Japan Market Share, By Phase, 2021

Figure 103: South Korea Market Value (US$ million) and Forecast, 2022 to 2032

Figure 104: South Korea Market Share, By Study Design, 2021

Figure 105: South Korea Market Share, By Phase, 2021

Figure 106: GCC Countries Market Value (US$ million) and Forecast, 2022 to 2032

Figure 107: GCC Countries Market Share, By Study Design, 2021

Figure 108: GCC Countries Market Share, By Phase, 2021

Figure 109: South Africa Market Value (US$ million) and Forecast, 2022 to 2032

Figure 110: South Africa Market Share, By Study Design, 2021

Figure 111: South Africa Market Share, By Phase, 2021

Figure 112: Turkey Market Value (US$ million) and Forecast, 2022 to 2032

Figure 113: Turkey Market Share, By Study Design, 2021

Figure 114: Turkey Market Share, By Phase, 2021

November 2022

REP-GB-15802

250 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -

Non-Alcoholic Steatohepatitis Clinical Trials Market

Non-Alcoholic Steatohepatitis Clinical Trials Market By Study Design, Phase & Region | Forecast 2022 to 2032